Genprex Inc Stock Price, News & Analysis

Genprex, Inc. (GNPX) announced positive preclinical data on NPRL2 gene therapy at the AACR 2023 annual meeting, demonstrating effective anti-tumor activity against non-small cell lung cancer (NSCLC) resistant to pembrolizumab using their ONCOPREX® delivery system. This research, conducted in a humanized mouse model, showcases the potential of NPRL2 as a new drug candidate for NSCLC. The study highlights that NPRL2 therapy significantly improved anti-tumor immune responses compared to pembrolizumab alone. Genprex's ONCOPREX® system effectively delivers tumor suppressor genes intravenously, potentially positioning the company to expand its oncology pipeline. Current clinical trials include REQORSA® in combination with Tagrisso® and Keytruda® for late-stage NSCLC, with promising outcomes paving the way for future therapeutic developments.

Genprex, Inc. (NASDAQ: GNPX) announced pre-clinical findings revealing that the tumor suppressor gene TUSC2 significantly inhibits glioblastoma. Independent researchers presented these results at the 2023 American Association for Cancer Research Annual Meeting. The study showed that TUSC2 overexpression decreases colony and neurosphere formation, induces apoptosis in glioblastoma cells in vitro, and suppresses tumor growth in vivo. Additionally, the research found that TUSC2 protein levels were significantly lower in glioblastoma compared to normal brain tissue. The study supports ongoing investigations into TUSC2 as a potential target for various cancers, enhancing the therapeutic potential of Genprex's lead drug candidate, REQORSA®, which is currently being evaluated for non-small cell lung cancer and small cell lung cancer.

Genprex (GNPX), a clinical-stage gene therapy company, announced its support for the FDA's initiative aimed at expediting gene therapy development for rare diseases. The FDA's new approach will allow biomarkers to substitute for traditional biological indicators in clinical trials, potentially accelerating approval processes. Rodney Varner, CEO, emphasized that this initiative is beneficial for advancing Genprex's pipeline of gene therapies, particularly for patients with limited treatment options in cancer and diabetes. The company is utilizing its proprietary ONCOPREX Nanoparticle Delivery System for its oncology program, currently in clinical trials.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announces that Dr. Hemant Kumar, Chief Manufacturing and Technology Officer, will speak at the Bioprocessing Summit Europe in Barcelona, Spain from March 14-16, 2023. His presentation titled Managing Headwinds Due to CDMO's M&A Activities will discuss how recent mergers and acquisitions in the Contract Development and Manufacturing Organization (CDMO) sector affect gene therapy innovations. Dr. Kumar emphasizes the need for partnerships to navigate increased costs and regulatory delays, highlighting Genprex's commitment to developing life-changing therapies for cancer and diabetes. More details can be found at www.genprex.com.

Genprex, a clinical-stage gene therapy company focusing on treatments for cancer and diabetes, has announced its participation in two major conferences in March 2023. The Roth Conference will occur from March 12-14 in Laguna Niguel, California, and the BIO-Europe Spring will take place from March 20-22 in Basel, Switzerland. CFO Ryan Confer will represent Genprex at the Roth Conference, while multiple executives will attend BIO-Europe Spring. CEO Rodney Varner expressed enthusiasm about showcasing their innovative gene therapies, including updates on the REQORSA clinical trial for lung cancer and data on therapies for Type 1 diabetes.

Genprex, Inc. (NASDAQ: GNPX) announced a registered direct offering with a healthcare-focused institutional investor, involving 3,809,524 shares and warrants priced at $1.05 per share. The warrants will have an exercise price of $1.10 and expire in five years. The offering, expected to close on or about March 1, 2023, will generate approximately $4 million in gross proceeds, earmarked for general working capital. A.G.P./Alliance Global Partners acts as the sole placement agent. This transaction is conducted under an existing shelf registration statement filed with the SEC.